Overall pharmaceutical deal-making activity fell 18% in 2011 as drugmakers cut R&D expenditure and streamlined their research activities.
That is the key finding in the latest report from UK advisory firm PharmaVentures. According to a review of its database, which contains over 43,000 deal records, licensing pacts fell by 16% "while the most sought-after assets commanded sizeable premiums in 2011". In contrast, M&A activity remained robust in 2011 and deal values actually rose by 30%, although the authors of the report note that contingent payments were commonplace, eg Sanofi's acquisition of Genzyme Corp.
In terms of therapeutic area, the research reveals that "oncology-based deals continued to dominate the landscape" with Roche being the most prolific firm. It also notes that emerging markets remained at the top of the deal-making agenda in 2011, especially India and China.
The report highlights AstraZeneca's proposed acquisition of Guangdong BeiKang Pharmaceutical, a Chinese manufacturer of generic injectable antibiotics, while other big pharma companies "went down the joint venture route", notably the Bayer/Zydus Cadila and Merck & Co/Sun Pharmaceutical Industries alliances in India.
Fintan Walton, PharmaVentures chief executive, noted that the industry is undergoing "a rapid and major transformation driven by declining R&D productivity and blockbuster drugs coming off-patent". However, "with quality assets commanding higher premiums there is still a significant opportunity for great deals to be done,” he added.
The views expressed in the following comments are not those of PharmaTimes or any connected third party and belong specifically to the individual who made that comment. We accept no liability for the comments made and always advise users to exercise caution.